Bibliography
- GOULD AL, ROSSOUW JE, SANTANELLO NC, HEYSE JF,FURBERG CD: Cholesterol reduction yields clinical benefit - impact of statin trials. Circulation (1998) 97:946–952.
- PACKARD CJ, SHEPHERD J: Lipoprotein heterogeneityand apolipoprotein-B metabolism. Arteriosclorsis Thromb. Vasc. Biol. (1997) 17:3542–3556.
- SUPERKO HR: What can we learn about dense low den-sity lipoprotein and lipoprotein particles from clinical trials? Curr. Opin. Lipidol. (1996) 7:363–368.
- RIGOTTI A, TRIGATTI B, BABITT J, PENMAN M, XU SH, KRIEGER M: Scavenger receptor BI - a cell-surface re-ceptor for high-density-lipoprotein. Curr. Opin. Lipidol. (1997) 8:181–188.
- SCHOONJANS K, MARTIN G, STAELS B, AUWERX J: Per-oxisome proliferator-activated receptors: orphans with ligands and functions. Curr. Opin. Lipidol. (1997) 8:159–166.
- SHARP D, BLINDERMAN L, COMBS KA et al.: Cloning andgene defects in microsomal triglyceride transfer pro-teinassociated with abetalipoproteinaemia. Nature (1993) 365:65–69.
- SCHNEIDER WJ, NIMPF J, BUJO H: Novel members of the low density lipoprotein receptor superfamily and their potential roles in lipid metabolism. Curr. Opin. Lipidol. (1997) 8:315–319
- STEIN JH, ROSENSON RS: Lipoprotein Lp(a) excess and coronary heart disease. Arch. Intern. Med. (1997) 157:1170–1176.
- ANGELIN B: Therapy for lowering lipoprotein(a) lev-els. Curr. Opin. Lipdol. (1997) 8:337–341.
- KRAUSE BK: CI-1011 lowers lipoprotein(a) and plasma-cholesterol concentrations in chow-fed cyno-molgus monkeys. Atherosclerosis (1998) 136:79–87.
- NICOLOSI RJ, WILSON TA, KRAUSE BR: The ACAT inhibi-tor CI-1011 is effective in the prevention and regres-sion of aortic fatty streak area in hamsters. Atherosclerosis (1998) 136:77–85.
- BISGAIER CL, ESSENBURG AD, BARNETT BC et al.: Anovel compound that elevates high-density-lipoprotein and activates the peroxisome proliferator activated receptor. J. Lipid Res. (1998) 39:17–30.
- OLSSON AG, YUAN XM: Antioxidants and the prevention of atherosclerosis. Curr. Opin. Lipidol (1996) 7:374–380.
- SUCKLING KE: The vulnerable atherosclerotic plaque. In: Emerging Drugs. The Prospect for Improved Medicines. WC Bowman, JD Fitzgerald, JB Taylor (Eds.), Ashley Publi-cations Ltd., London, UK (1998) 3:121–134.
- STEPHENS NG, PARSONS A, SCHOFIELD PM et al.: Ran-domised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet (1996) 347:781–786.
- TEW DG, SOUTHAN C, RICE SQJ et al.: Purification, prop-erties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipopro-teins. Arterioscl Thromb. Vasc. Biol. (1996) 16:591–599.
- MARTIN G, SCHOONJANS K, STAELS B, AUWERX J: PPAR activators improve glucose homeostasis by changing fatty acid partitioning. In: Atherosclerosis XI. Jacotot B, Mathe D, Fruchart J-C (Eds.), Elsevier Science, Singapore (1998)35–47.
- CHAPMAN MJ: Comparative analysis of mammalian plasma lipoproteins. Methods Enzymol. (1986) 128:70–143.
- SNOWDEN MM, GROVE RI: Gene therapy for cardiovas-cular disease. Exp. Opin. Ther. Patents (1998) 8:509–520.
- HOEG JM, SANTAMARINAFOJO S, BERARD AM et al.: Overexpression of lecithin, cholesterol acyltransfe-rase in transgenic rabbits prevents diet-induced athe-rosclerosis. Proc. Natl. Acad. Sci. USA (1996) 93:11448–11453.